Healthcare · Biotechnology

Gilead Sciences, Inc.

NASDAQGILD ISINUS3755581036 SEC CIK0000882095 Listed on NASDAQ · USD

$171.12 +1.39 (+0.82%) Pre-market $171.23 (+0.88%) ≈ ₹16,060 a share

Open chart

Price, last 12 months+42.82% in a year

Key numbers

Market value: $212.25B
P/E (TTM): -54.4
Forward P/E: 21.5
EPS (TTM): $-3.15
Dividend yield: 1.92%
Beta: 0.37
Day range: $169.00 – $171.70
52-week range: $116.88 – $176.58
Volume: 860,484
10-day avg volume: $7.63M
Revenue (TTM): $30.99B
EBITDA (TTM): $14.58B
Gross margin: 80.0%
Net margin: -12.5%
Return on equity: -22.3%
Debt / equity: 201.2%
Price / sales: 6.85
Shares out: 1.24B

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$7.11B$1.61B$1.43B

Dec 23

$6.69B$-4.32B$-4.17B

Mar 24

$6.95B$2.64B$1.61B

Jun 24

$7.55B$888.00M$1.25B

Sep 24

$7.57B$2.45B$1.78B

Dec 24

$6.67B$2.24B$1.32B

Mar 25

$7.08B$2.47B$1.96B

Jun 25

$7.77B$3.33B$3.05B

Sep 25

$7.93B$1.98B$2.18B

Dec 25

$6.96B$2.59B$2.02B

Mar 26

$7.80B$-10.39B$-10.50B

Jun 26

$8.30B$3.46B$2.43B

Sep 26

Revenue · QoQ (vs last quarter)

—-6.0%+4.0%+8.5%+0.3%-12%+6.2%+9.7%+2.0%-12%+12%+6.4%

Revenue · YoY (vs a year ago)

————+6.4%-0.3%+1.8%+3.0%+4.7%+4.4%+10%+6.8%

Net income · QoQ (vs last quarter)

—-392%+139%-22%+42%-26%+49%+56%-28%-7.4%-619%+123%

Net income · YoY (vs a year ago)

————+25%+132%+21%+144%+22%+54%-636%-20%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$7.11B	$6.69B	$6.95B	$7.55B	$7.57B	$6.67B	$7.08B	$7.77B	$7.93B	$6.96B	$7.80B	$8.30B
Cost of revenue	$2.09B	$1.55B	$1.54B	$1.57B	$1.58B	$1.54B	$1.50B	$1.57B	$1.62B	$1.45B	$1.58B	$1.57B
Gross profit	$5.02B	$5.13B	$5.41B	$5.97B	$5.99B	$5.13B	$5.58B	$6.20B	$6.30B	$5.52B	$6.22B	$6.73B
Gross margin	70.6%	76.8%	77.8%	79.1%	79.1%	76.9%	78.8%	79.8%	79.5%	79.2%	79.8%	81.1%
Selling, general & admin	$1.61B	$1.38B	$1.38B	$1.43B	$1.91B	$1.26B	$1.37B	$1.36B	$1.79B	$1.45B	$1.92B	$1.64B
Operating income	$1.61B	$-4.32B	$2.64B	$888.00M	$2.45B	$2.24B	$2.47B	$3.33B	$1.98B	$2.59B	$-10.39B	$3.46B
Operating margin	22.7%	-64.6%	38.0%	11.8%	32.4%	33.6%	34.9%	42.8%	25.0%	37.2%	-133.2%	41.7%
Interest expense	$252.00M	$254.00M	$237.00M	$238.00M	$248.00M	$260.00M	$254.00M	$256.00M	$254.00M	$240.00M	$247.00M	$269.00M
Pre-tax income	$1.65B	$-4.49B	$2.05B	$956.00M	$2.17B	$1.65B	$2.43B	$3.64B	$2.08B	$2.58B	$-10.25B	$3.06B
Income tax	$236.00M	$-315.00M	$438.00M	$-297.00M	$385.00M	$334.00M	$468.00M	$589.00M	$-105.00M	$559.00M	$242.00M	$634.00M
Net income	$1.43B	$-4.17B	$1.61B	$1.25B	$1.78B	$1.32B	$1.96B	$3.05B	$2.18B	$2.02B	$-10.50B	$2.43B
Net margin	20.1%	-62.4%	23.2%	16.6%	23.6%	19.7%	27.7%	39.3%	27.5%	29.0%	-134.5%	29.3%
EPS (diluted)	—	$-3.34	$1.29	$1.00	—	$1.04	$1.56	$2.43	—	$1.61	$-8.45	$1.94

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$22.13B$17.27B$5.46B

FY18

$22.45B$17.77B$5.39B

FY19

$24.69B$20.12B$123.00M

FY20

$27.31B$20.70B$6.23B

FY21

$27.28B$21.62B$4.59B

FY22

$27.12B$20.62B$5.67B

FY23

$28.75B$22.50B$480.00M

FY24

$29.44B$23.21B$8.51B

FY25

Revenue · YoY (vs a year ago)

—+1.5%+10.0%+11%-0.1%-0.6%+6.0%+2.4%

Net income · YoY (vs a year ago)

—-1.3%-98%+4,961%-26%+23%-92%+1,673%

RevenueGross profitNet incomeLine = trend

$4.17

FY18

$4.22

FY19

$0.10

FY20

$4.93

FY21

$3.64

FY22

$4.50

FY23

$0.38

FY24

$6.78

FY25

EPS (diluted) · YoY (vs a year ago)

—+1.2%-98%+4,830%-26%+24%-92%+1,684%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$22.13B	$22.45B	$24.69B	$27.31B	$27.28B	$27.12B	$28.75B	$29.44B
Revenue growth	—	1.5%	10.0%	10.6%	-0.1%	-0.6%	6.0%	2.4%
Cost of revenue	$4.85B	$4.68B	$4.57B	$6.60B	$5.66B	$6.50B	$6.25B	$6.23B
Gross profit	$17.27B	$17.77B	$20.12B	$20.70B	$21.62B	$20.62B	$22.50B	$23.21B
Gross margin	78.1%	79.2%	81.5%	75.8%	79.3%	76.0%	78.3%	78.8%
Research & development	$5.02B	$9.11B	—	—	—	—	—	—
Selling, general & admin	$4.06B	$4.38B	$5.15B	$5.25B	$5.67B	$6.09B	$6.09B	$5.77B
Operating income	$8.20B	$4.29B	$4.07B	$9.92B	$7.33B	$7.61B	$1.66B	$10.02B
Operating margin	37.1%	19.1%	16.5%	36.3%	26.9%	28.0%	5.8%	34.0%
Interest expense	$1.08B	$995.00M	$984.00M	$1.00B	$935.00M	$944.00M	$977.00M	$1.02B
Pre-tax income	$7.80B	$5.16B	$1.67B	$8.28B	$5.81B	$6.86B	$690.00M	$9.80B
Income tax	$2.34B	$-204.00M	$1.58B	$2.08B	$1.25B	$1.25B	$211.00M	$1.29B
Tax rate	30.0%	-4.0%	94.7%	25.1%	21.5%	18.2%	30.6%	13.1%
Net income	$5.46B	$5.39B	$123.00M	$6.23B	$4.59B	$5.67B	$480.00M	$8.51B
Net margin	24.7%	24.0%	0.5%	22.8%	16.8%	20.9%	1.7%	28.9%
EPS (diluted)	$4.17	$4.22	$0.10	$4.93	$3.64	$4.50	$0.38	$6.78

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$21.39B$27.32B$30.09B

FY18

$22.53B$24.59B$24.35B

FY19

$18.20B$31.40B$7.41B

FY20

$21.07B$26.70B$6.52B

FY21

$21.24B$25.23B$6.39B

FY22

$22.83B$24.99B$7.26B

FY23

$19.33B$26.71B$9.99B

FY24

$22.70B$24.94B$7.63B

FY25

Shareholders' equity · YoY (vs a year ago)

—+5.3%-19%+16%+0.8%+7.5%-15%+17%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$17.94B	$11.63B	$6.00B	$5.34B	$5.41B	$6.09B	$9.99B	$7.56B
Short-term investments	$12.15B	$12.72B	$1.41B	$1.18B	$973.00M	$1.18B	$0	$68.00M
Current assets	$35.84B	$30.30B	$16.00B	$14.77B	$14.44B	$16.09B	$19.17B	$18.34B
Total assets	$63.68B	$61.63B	$68.41B	$67.95B	$63.17B	$62.13B	$59.00B	$59.02B
Current liabilities	$10.61B	$9.76B	$11.40B	$11.61B	$11.24B	$11.28B	$12.00B	$11.81B
Long-term debt	$24.57B	$22.09B	$28.65B	$25.18B	$22.96B	$23.19B	$24.90B	$22.13B
Short-term debt	$2.75B	$2.50B	$2.76B	$1.52B	$2.27B	$1.80B	$1.82B	$2.81B
Total debt	$27.32B	$24.59B	$31.40B	$26.70B	$25.23B	$24.99B	$26.71B	$24.94B
Shareholders' equity	$21.39B	$22.53B	$18.20B	$21.07B	$21.24B	$22.83B	$19.33B	$22.70B
Current ratio	3.38	3.10	1.40	1.27	1.29	1.43	1.60	1.55
Debt / equity	1.28	1.09	1.73	1.27	1.19	1.09	1.38	1.10
Return on equity	25.5%	23.9%	0.7%	29.5%	21.6%	24.8%	2.5%	37.5%

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$8.40B$7.48B$5.87B

FY18

$9.14B$8.32B$4.97B

FY19

$8.17B$7.52B$5.03B

FY20

$11.38B$10.81B$4.15B

FY21

$9.07B$8.34B$5.11B

FY22

$8.01B$7.42B$4.81B

FY23

$10.83B$10.31B$5.07B

FY24

$10.02B$9.46B$5.93B

FY25

Operating cash flow · YoY (vs a year ago)

—+8.9%-11%+39%-20%-12%+35%-7.5%

Free cash flow · YoY (vs a year ago)

—+11%-9.6%+44%-23%-11%+39%-8.2%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$8.40B	$9.14B	$8.17B	$11.38B	$9.07B	$8.01B	$10.83B	$10.02B
Capital spending	$-924.00M	$-825.00M	$-650.00M	$-579.00M	$-728.00M	$-585.00M	$-523.00M	$-563.00M
Free cash flow	$7.48B	$8.32B	$7.52B	$10.81B	$8.34B	$7.42B	$10.31B	$9.46B
FCF margin	33.8%	37.1%	30.5%	39.6%	30.6%	27.4%	35.8%	32.1%
Stock-based pay	$845.00M	$636.00M	$643.00M	$635.00M	$637.00M	$766.00M	$835.00M	$894.00M
Cash from investing	$14.36B	$-7.82B	$-14.62B	$-3.13B	$-2.47B	$-2.27B	$-3.45B	$-4.79B
Cash from financing	$-12.32B	$-7.63B	$770.00M	$-8.88B	$-6.47B	$-5.13B	$-3.43B	$-7.75B
Dividends paid	$-2.97B	$-3.22B	$-3.45B	$-3.61B	$-3.71B	$-3.81B	$-3.92B	$-4.00B
Share buybacks	$-2.90B	$-1.75B	$-1.58B	$-546.00M	$-1.40B	$-1.00B	$-1.15B	$-1.92B

About

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Gilead Sciences, Inc.
Ticker: GILD
Exchange: NASDAQ
ISIN: US3755581036
SEC CIK: 0000882095
Sector: Healthcare
Industry: Biotechnology
SEC industry (SIC): Biological Products, (no Diagnostic Substances) (2836)
Incorporated in: Delaware
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 24 Feb 2026
CEO: Daniel O'Day
Chair: Daniel O'Day
Headquarters: Foster City
Address: 333 Lakeside Dr, Foster City, Ca 94404
Founded: 1987
Employees: 17,000
Trades in: US dollars (USD)
Website: gilead.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Gilead Sciences, Inc.

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers